221 related articles for article (PubMed ID: 30070630)
21. Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice.
Eekman DA; Bultink IE; Heijboer AC; Dijkmans BA; Lems WF
BMC Musculoskelet Disord; 2011 Jul; 12():167. PubMed ID: 21774839
[TBL] [Abstract][Full Text] [Related]
22. Role of biochemical markers in the management of osteoporosis.
Henriksen K; Christiansen C; Karsdal MA
Climacteric; 2015; 18 Suppl 2():10-8. PubMed ID: 26507704
[TBL] [Abstract][Full Text] [Related]
23. The effects of discontinuing long term alendronate therapy in a clinical practice setting.
Silva AG; Vieira JG; Kunii IS; Lana JM; Lazaretti-Castro M
Arq Bras Endocrinol Metabol; 2011 Jun; 55(4):272-8. PubMed ID: 21779630
[TBL] [Abstract][Full Text] [Related]
24. Predictive Power of Bone Turnover Biomarkers to Estimate Bone Mineral Density after Kidney Transplantation with or without Denosumab: A post hoc Analysis of the POSTOP Study.
Heimgartner N; Graf N; Frey D; Saleh L; Wüthrich RP; Bonani M
Kidney Blood Press Res; 2020; 45(5):758-767. PubMed ID: 32998144
[TBL] [Abstract][Full Text] [Related]
25. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
26. Observational Study to Evaluate the Effect of Epidural Steroid Injection on Bone Mineral Density and Bone Turnover Markers.
Jain A; Gupta P; Chaurasia R; Singh M; Pandey S
Pain Physician; 2020 Sep; 23(5):E517-E524. PubMed ID: 32967402
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
[TBL] [Abstract][Full Text] [Related]
28. The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study.
Zhao J; Xia W; Nie M; Zheng X; Wang Q; Wang X; Wang W; Ning Z; Huang W; Jiang Y; Li M; Wang O; Xing X; Sun Y; Luo L; He S; Yu W; Lin Q; Pei Y; Zhang F; Han Y; Tong Y; Che Y; Shen R; Hu Y; Zhou X; Xu L
Menopause; 2011 Nov; 18(11):1237-43. PubMed ID: 21747303
[TBL] [Abstract][Full Text] [Related]
29. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men.
Finkelstein JS; Leder BZ; Burnett SM; Wyland JJ; Lee H; de la Paz AV; Gibson K; Neer RM
J Clin Endocrinol Metab; 2006 Aug; 91(8):2882-7. PubMed ID: 16684825
[TBL] [Abstract][Full Text] [Related]
30. Bone turnover markers are associated with higher cortical porosity, thinner cortices, and larger size of the proximal femur and non-vertebral fractures.
Shigdel R; Osima M; Ahmed LA; Joakimsen RM; Eriksen EF; Zebaze R; Bjørnerem Å
Bone; 2015 Dec; 81():1-6. PubMed ID: 26112819
[TBL] [Abstract][Full Text] [Related]
31. Traditional and novel bone remodeling markers in premenopausal and postmenopausal women.
Botella S; Restituto P; Monreal I; Colina I; Calleja A; Varo N
J Clin Endocrinol Metab; 2013 Nov; 98(11):E1740-8. PubMed ID: 24001743
[TBL] [Abstract][Full Text] [Related]
32. The Utility of Biomarkers in Osteoporosis Management.
Garnero P
Mol Diagn Ther; 2017 Aug; 21(4):401-418. PubMed ID: 28271451
[TBL] [Abstract][Full Text] [Related]
33. Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis.
Lorentzon M; Branco J; Brandi ML; Bruyère O; Chapurlat R; Cooper C; Cortet B; Diez-Perez A; Ferrari S; Gasparik A; Herrmann M; Jorgensen NR; Kanis J; Kaufman JM; Laslop A; Locquet M; Matijevic R; McCloskey E; Minisola S; Pikner R; Reginster JY; Rizzoli R; Szulc P; Vlaskovska M; Cavalier E
Adv Ther; 2019 Oct; 36(10):2811-2824. PubMed ID: 31440982
[TBL] [Abstract][Full Text] [Related]
34. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
[TBL] [Abstract][Full Text] [Related]
35. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
36. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
[TBL] [Abstract][Full Text] [Related]
37. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
38. [Significance of Bone Turnover Marker Measurement in the Treatment of Osteoporosis].
Miura M; Satoh Y
Yakugaku Zasshi; 2019; 139(1):27-33. PubMed ID: 30606924
[TBL] [Abstract][Full Text] [Related]
39. [The role of biochemical markers of bone turnover in the diagnosis of osteoporosis and predicting fracture risk].
Mohamed Y; Haifa H; Datel O; Fadoua HN; Smeh BH; Mahbouba J; Saoussen Z; Bejia I; Mongi T; Mohamed FN; Naceur B
Tunis Med; 2014 May; 92(5):304-10. PubMed ID: 25504382
[TBL] [Abstract][Full Text] [Related]
40. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
Diez-Perez A; Naylor KE; Abrahamsen B; Agnusdei D; Brandi ML; Cooper C; Dennison E; Eriksen EF; Gold DT; Guañabens N; Hadji P; Hiligsmann M; Horne R; Josse R; Kanis JA; Obermayer-Pietsch B; Prieto-Alhambra D; Reginster JY; Rizzoli R; Silverman S; Zillikens MC; Eastell R;
Osteoporos Int; 2017 Mar; 28(3):767-774. PubMed ID: 28093634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
